^{a. Primary adverse events included death, atrioesophageal fistula, myocardial infarction, stroke/cerebrovascular accident, thromboembolism, transient ischemic attack, phrenic nerve injury/diaphragmatic paralysis, heart block, PV stenosis, pulmonary edema (respiratory insufficiency), vagal nerve injury, pericarditis, and major vascular access complication/bleeding. Atrioesophageal fistula and PV stenosis that occurring 7–90 days postablation, and cardiac tamponade/perforation occurring ≤30 days of ablation, were also considered primary adverse events.
b. The primary effectiveness endpoint was freedom from documented recurrence of AF/AFL/AT ≥30 seconds and freedom from 3 additional failure modes: acute procedural failure (failure to confirm entrance block in all PVs or use of nonstudy catheter), repeat ablation failure (>2 repeat ablation during blanking period, use of nonstudy catheter for repeat ablation during blanking, or any repeat ablation postblanking), and AAD failure (new AAD/higher dose postblanking).}